The Daily Dose: Adult RSV Vaccine

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study.

The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.


On October 14, 2022, we reviewed a pivotal phase 3 clinical trial of an investigational respiratory syncytial virus (RSV) vaccine (RSVPreF3 OA) for older adults.

The study

The phase 3 randomized placebo-controlled AReSVi-006 trial enrolled 25 000 participants from 17 countries to evaluate efficacy of a single dose of the adjuvanted RSVPreF3 OA investigational vaccine in adults aged ≥60 years. Findings, which will be presented at IDWeek 2002 later this month, showed overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease, satisfying the trial’s primary endpoint.

A note from the manufacturer

“These are truly exceptional results given that today RSV remains one of the major infectious diseases without a vaccine, despite over 60 years of research,” said GSK chief scientific officer Tony Wood in a statement.

The company believes that these robust findings suggest the potential for RSVPreF3 OA to help reduce the global burden of RSV-LRTD, and particularly among older and the most vulnerable adults.

Click here for the full study review.